SCHEMBL6076212

SCHEMBL6076212

CCOC(C(=O)O)C(CC)c1ccc(OCCn2c(C)ccc2-c2ccc(OC(C)C)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
CHRM1 P11229 1/20 0.54
TBXA2R P21731 1/20 0.54
PTGS1 P23219 1/20 0.54
SLC6A2 P23975 1/20 0.54
PDE4A P27815 1/20 0.54
ADRA1A P35348 1/20 0.54
DRD3 P35462 1/20 0.54
PPARG P37231 11/20 0.37
PPARA Q07869 11/20 0.37
PPARD Q03181 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
BACE1 P56817 2/20 0.34
BCL2 P10415 1/20 0.34
MDM2 Q00987 1/20 0.34
MCL1 Q07820 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6076265 0.93 PGR (0.57) PGRADORA3CHRM1TBXA2RPTGS1
SCHEMBL6076601 0.91 PGR (0.55) PGRADORA3CHRM1TBXA2RPTGS1
SCHEMBL542803 0.90 PGR (0.54) PGRADORA3CHRM1TBXA2RPTGS1
SCHEMBL6075613 0.88 DRD3 (0.52) PGRADORA3CHRM1TBXA2RPTGS1
SCHEMBL6076735 0.88 PGR (0.54) PGRADORA3CHRM1TBXA2RPTGS1
SCHEMBL7616870 0.86 PGR (0.47) PGRADORA3CHRM1TBXA2RPTGS1
SCHEMBL6076665 0.84 PGR (0.45) PGRADORA3CHRM1TBXA2RPTGS1
SCHEMBL6077620 0.83 PGR (0.47) PGRADORA3CHRM1TBXA2RPTGS1
SCHEMBL6076948 0.83 PGR (0.45) PGRADORA3CHRM1TBXA2RPTGS1
SCHEMBL6076397 0.82 PGR (0.44) PGRADORA3CHRM1TBXA2RPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236254-A1 Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine CADILA HEALTHCARE LIMITED (IN) 2003-12-25 US claimed
US-7041837-B2 Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine CADILLA HEALTHCARE LIMITED (IN) 2006-05-09 US disclosed
US-20030236254-A1 Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine CADILA HEALTHCARE LIMITED (IN) 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236254-A1 Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine LIPA, LIPC, CYP46A1 PGR 2271/4885ADORA3 2484/4885CHRM1 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.